V5 Ultimate
Ultimate
PricingResourcesCompany
English (original)DeutschΕλληνικάEspañolFrançaisItalianoעברית日本語한국어NederlandsPolskiPortuguêsSvenska
Talk to us Log in Start free trial
Food & Beverage
  • Bakery & Confectionery
  • Food Processing
  • Ingredients & Dry Mixes
  • Sausage & Meat Products
  • Produce Packing
  • Pet Food & Pet Supplements
  • Dairy & Chilled Foods
  • Beverages & Liquid Manufacturing
  • Infant Formula
Pharma & Life Sciences
  • Radiopharmaceuticals
  • Pharmaceutical
  • Medical Devices
  • Veterinary Pharmaceuticals
  • Blood & Tissue
  • Diagnostics & IVD Kits
  • Reference Materials & Standards
  • OTC Topical Creams & Gels
Supplements & Personal Care
  • Dietary Supplements
  • Cosmetics & Personal Care
  • Cannabis & Hemp Manufacturing
  • Fragrances & Perfumery
  • Soaps & Personal Hygiene
  • Botanical Extracts & Essential Oils
Chemicals & Materials
  • Plastics & Resins
  • Agricultural Chemicals
  • Specialty & Industrial Chemicals
  • Printing Inks, Pigments & Construction Chemicals
  • Lubricants & Metalworking Fluids
  • Coatings, Adhesives & Sealants
Other Manufacturing
  • Consumer Products
  • Electronics & Electrical Assembly
  • Textiles & Nonwoven
  • Contract Manufacturing & Co-Packing
  • Packaging & Food-Contact Materials
  • Regulated Warehousing & Distribution
Explore all industries
  • Warehouse & TraceabilityReceive, store, pick and trace
  • Production & PlanningPlan jobs and guide production
  • Quality & LaboratoryTest, investigate and review
  • Documents & TrainingControl procedures and qualifications
  • Equipment & PerformanceMaintain assets and measure losses
  • Orders & IntegrationsConnect customers, suppliers and systems
  • Outputs & InsightsReports, KPIs and label design
Why V5? Product & Features
Why V5?Product & Features
  • Warehouse & TraceabilityReceive, store, pick and trace
  • Production & PlanningPlan jobs and guide production
  • Quality & LaboratoryTest, investigate and review
  • Documents & TrainingControl procedures and qualifications
  • Equipment & PerformanceMaintain assets and measure losses
  • Orders & IntegrationsConnect customers, suppliers and systems
  • Outputs & InsightsReports, KPIs and label design
Explore all industries
    • Bakery & Confectionery
    • Food Processing
    • Ingredients & Dry Mixes
    • Sausage & Meat Products
    • Produce Packing
    • Pet Food & Pet Supplements
    • Dairy & Chilled Foods
    • Beverages & Liquid Manufacturing
    • Infant Formula
    • Radiopharmaceuticals
    • Pharmaceutical
    • Medical Devices
    • Veterinary Pharmaceuticals
    • Blood & Tissue
    • Diagnostics & IVD Kits
    • Reference Materials & Standards
    • OTC Topical Creams & Gels
    • Dietary Supplements
    • Cosmetics & Personal Care
    • Cannabis & Hemp Manufacturing
    • Fragrances & Perfumery
    • Soaps & Personal Hygiene
    • Botanical Extracts & Essential Oils
    • Plastics & Resins
    • Agricultural Chemicals
    • Specialty & Industrial Chemicals
    • Printing Inks, Pigments & Construction Chemicals
    • Lubricants & Metalworking Fluids
    • Coatings, Adhesives & Sealants
    • Consumer Products
    • Electronics & Electrical Assembly
    • Textiles & Nonwoven
    • Contract Manufacturing & Co-Packing
    • Packaging & Food-Contact Materials
    • Regulated Warehousing & Distribution
PricingResourcesCompany
Start free trial Log in Talk to us
HomeGlossaryCAR
Quality · The complete guide

Corrective Action Request (CAR)

In short

Follow a quality problem from a documented request through investigation, supplier response and evidence-based closure.

4,088 words · ~19 min read
Two quality staff in protective clothing review a rejected supplier lot on a tablet beside a quarantine cage
A corrective action request asks an owner to find and remove the cause of a problem.
On this page
  1. 01What a Corrective Action Request asks someone to do
  2. 02CAR, SCAR, CAPA and deviation: different records, different jobs
  3. 03Regulatory context: US drug review, device QMSR and ICH guidance
  4. 04CAR fields that connect the problem to closure evidence
  5. 05From CAR intake to investigation, action and verified closure
  6. 06Route by product risk, recurrence and ownership
  7. 07Supplier CARs: assess the response, not just its arrival
  8. 08Effectiveness checks and metrics that distinguish completion from success
  9. 09Keep evidence connected when systems or supplier responses fail
  10. 10CAR failure modes and a practical implementation checklist
On this page · 10 sections
  1. 1What a Corrective Action Request asks someone to do
  2. 2CAR, SCAR, CAPA and deviation: different records, different jobs
  3. 3Regulatory context: US drug review, device QMSR and ICH guidance
  4. 4CAR fields that connect the problem to closure evidence
  5. 5From CAR intake to investigation, action and verified closure
  6. 6Route by product risk, recurrence and ownership
  7. 7Supplier CARs: assess the response, not just its arrival
  8. 8Effectiveness checks and metrics that distinguish completion from success
  9. 9Keep evidence connected when systems or supplier responses fail
  10. 10CAR failure modes and a practical implementation checklist
AI · Explain it for MY operation

How does CAR apply to your shop floor?

Pick your industry and scale — Ask V5 rewrites the definition in your context, gives a worked example, and shows what V5 does on day one.

Your scale

01What a Corrective Action Request asks someone to do

A Corrective Action Request (CAR) is a documented request for a responsible person or organisation to investigate a quality problem, address its cause and provide evidence for review. CAR is industry terminology, not a defined regulatory term. Its operational meaning comes from the organisation’s quality procedures and, for supplier requests, the agreed customer–supplier process.

The request identifies the problem, assigns accountability and establishes what response is expected. It turns an observation into an explicit assignment: who will investigate, what issue they will address and what evidence the reviewer expects to receive. Issuing a CAR does not establish a root cause or demonstrate that an action worked. Those conclusions depend on subsequent investigation and evaluation, not on the existence of the request.

Typical origins include a QA audit finding, recurring nonconformance, complaint trend, manufacturing deviation or supplier problem such as a receiving discrepancy. Keep the originating evidence identifiable rather than replacing it with a summary. A reviewer needs to trace the request back to the observation, affected material or process, and supporting records. Describe what was observed without presenting an untested explanation as the cause.

A supplier corrective action request is commonly abbreviated SCAR. It directs the request to a supplier through the agreed customer–supplier process. The supplier section addresses responsibilities for that exchange; the starting purpose remains a clear problem statement and an accountable request for an evidence-based response.

02CAR, SCAR, CAPA and deviation: different records, different jobs

In industry practice, a CAR requests work; it is not necessarily the record of the original event, the action performed or the broader CAPA record. The distinctions below describe common operational uses, not a universal record hierarchy.

TermOperational purposeTypical contents or outputRelationship to the CAR
CARRequest investigation and a response to a problemProblem statement, requested work, owner, response expectationsTracks the request and response
SCARDirect a corrective action request to a supplierSupplier-facing findings, affected deliveries, response and supporting evidenceSupplier-facing form of CAR
DeviationDocument a departure from an expected process or instructionEvent details, impact assessment, investigation referenceMay originate a CAR
Nonconformance recordDocument a failure to meet a specified requirementRequirement, observed failure, affected material, dispositionMay originate or support a CAR
CorrectionResolve the immediate problemRework, replacement or another immediate remedyMay be requested without resolving the cause
Corrective actionAddress the cause to prevent recurrenceImplemented process or control change with supporting evidenceWork requested by a CAR
CAPA recordCoordinate investigation, actions and effectiveness evaluationCause analysis, action plan, responsibilities, evaluation and closureMay contain or link to CARs

Sites commonly distinguish a deviation from a nonconformance through their procedures; others use overlapping categories. Correcting an incorrect label resolves the immediate defect. Changing the selection control that allowed that label addresses its cause. Neither the category name nor completion of the correction establishes that corrective action succeeded.

A CAR can link to an existing investigation or CAPA rather than duplicate its analysis. Relationships can be many-to-many: related findings may share an investigation, while a broader CAPA may coordinate supplier requests and internal actions. Preserve each finding’s identity and the evidence supporting its resolution. Escalation depends on the site’s criteria, not the abbreviation on the form; CAPA effectiveness evaluation belongs with the coordinated action plan.

03Regulatory context: US drug review, device QMSR and ICH guidance

Corrective action request is an industry-practice label, not a defined regulatory term. A site's choice to call a record a CAR does not establish which legal framework applies. Keep the applicable obligation or guidance separate from the local procedure that names, routes and closes the request.

Jurisdiction and product contextAuthority typeRelevant referenceRelationship to a CAR
US drugsBinding regulation21 CFR 211.192Check this provision for the scope of production-record review and investigation provisions. Treat the CAR as an operational record choice, not a substitute for assessing the applicable rule.
US medical devices under the QMSRBinding regulation21 CFR 820.10(a)Requires a manufacturer to document a quality management system that complies with the applicable requirements of ISO 13485 (incorporated by reference, see § 820.7). ISO 13485 itself was not reviewed here; a CAR's local title does not establish its relationship to that framework.
Pharmaceutical quality systems using international ICH guidanceOfficial guidanceICH Q10 section 3.2.2For pharmaceutical quality systems using international ICH guidance, this section recommends a structured investigation aimed at determining root cause, with investigation effort, formality and documentation proportionate to risk. A CAR procedure can use these recommendations to shape the response requested.
Food, dietary supplements, chemicals and other marketsProduct- and jurisdiction-specific framework; CAR naming is practiceCheck the applicable framework separatelyDo not transfer US drug or device provisions across categories merely because the organisation uses the same CAR form.

In practice, procedures commonly map each CAR to its initiating record and identify the basis for the requested response: an applicable provision, a guidance recommendation or an internal control. This makes review more precise than attaching a generic regulatory reference to every request. For device-specific context, see FDA QMSR and the distinction between QMSR and ISO 13485.

04CAR fields that connect the problem to closure evidence

A useful CAR field model connects the observation, requested response and acceptance decision without turning the request into a duplicate investigation file. The following is a suggested practice model, not a prescribed regulatory form. Use stable identifiers and explicit relationships so reviewers can follow each conclusion back to its evidence.

Field groupTypical fieldsReview question
Identificationcar_id, origin_record_id, site_id, supplier_id where applicable, detected_atCan the request be traced to its originating observation?
Problem statementproblem_statement, specification/procedure reference and revision, observed condition, evidence referencesAre observed facts distinguishable from hypotheses?
Affected scopeproduct_id, lot_ids, equipment_ids, scope rationaleWhat is affected, and what supports the boundaries?
Responsibilityowner_id, reviewer_id, severity, escalation_owner_idWho supplies evidence, and who has authority to accept it?
Containmentcontainment_record_idWhere are temporary controls and their status documented?
Investigation linksinvestigation_id, capa_id, change_control_idCan reviewers reach the applicable controlled records?
Action commitmentsaction_ids, response_due_at, action_due_at, action ownersAre response delivery and action completion separately accountable?
Effectiveness planningeffectiveness_check_ids, acceptance_criteria, verification_method, exposure_basisWhat evidence would demonstrate success under relevant operating conditions?
Closureresult, decision, rationale, approved_by, approved_atDoes the authorised decision follow from the recorded results?

Describe the applicable expectation and observed condition before proposing a cause; keep hypotheses separately labelled. Retain authoritative investigations, CAPA records and change documents in their controlled locations, linking the relevant revision rather than copying competing versions. Store acceptance_criteria, verification_method and exposure_basis with each effectiveness check; reference those checks at closure. A target date is not an acceptance criterion: it schedules work but does not establish whether the action succeeded.

Companion data model

Suggested joins, with arrows pointing from foreign keys to referenced keys:

CAR.origin_record_id → OriginRecord.record_id SupplierResponse.car_id → CAR.car_id Action.car_id → CAR.car_id Action.supplier_response_id → SupplierResponse.response_id, when applicable EffectivenessCheck.action_id → Action.action_id ClosureDecision.car_id → CAR.car_id ClosureCheck.decision_id → ClosureDecision.decision_id ClosureCheck.check_id → EffectivenessCheck.check_id

Here, ClosureCheck links a decision to every check considered. Action and check identifier lists in the field table represent linked records, not comma-separated text. Use junction records where actions are shared across requests or checks assess multiple actions. Preserve supplier response revisions with their evidence references, and identify the response supporting each commitment. Record the evidence provider separately from the accepting reviewer; approved_by identifies the human authorising closure, not the person merely uploading the response.

CAR Records and Evidence Relationships

CAR

Owns scope and accountability.

  • car_id
  • owner_id
  • scope
  • status

Origin Link

Preserves the initiating evidence.

  • car_id
  • origin_record_id
  • evidence_uri

Supplier Response

Retains each submitted version.

  • car_id
  • supplier_id
  • response_version
  • received_at

Action

Links commitments to implementation.

  • car_id
  • action_id
  • owner_id
  • implementation_evidence

Effectiveness Check

Records criteria and observations.

  • car_id
  • action_id
  • acceptance_criteria
  • result

Closure Decision

Preserves human approval rationale.

  • car_id
  • decision
  • rationale
  • approved_by
  • approved_at
Suggested model: car_id connects the request to its supporting records.

05From CAR intake to investigation, action and verified closure

This illustrative industry-practice workflow uses evidence gates rather than treating a response as closure. Local procedures determine routing and approval authority; incomplete evidence sends the request back to the responsible owner.

Intake and acknowledgement → Containment and scope → Investigation or investigation linkage → Action-plan review → Implementation → Effectiveness evaluation → Closure decision

Gate and responsible roleEvidence and progression decision
Intake — CAR coordinatorLink the originating observation and record owner acknowledgement. Proceed when the concern and accountable owner are clear.
Containment — operations owner with quality reviewerDocument interim controls, potentially affected material and scope boundaries. Decide whether controls adequately protect operations while investigation continues.
Investigation — investigator with quality reviewerRecord findings and routing rationale: use the originating record if sufficient, extend an existing CAPA if its scope fits, or justify a separate CAPA. Avoid automatic escalation.
Action-plan review — process owner and quality approverReview cause-to-action links, responsibilities and effectiveness criteria. Authorise implementation when the plan addresses supported causes and applicable change controls.
Implementation — action ownersAttach approved changes, execution records and revised instructions. Confirm completion before assessing whether the actions worked.
Effectiveness — designated evaluatorCompare challenge or operating evidence with predefined criteria. Decide whether results support success, more observation or renewed investigation.
Closure — authorised quality approverReview scope, outstanding risks and the evidence chain. Record the human decision to close, defer or return for further work.

Worked case: dispensing configuration

Assume an internal pharmaceutical dispensing discrepancy is associated with a balance-unit configuration; mass observations are recorded in grams. Link the CAR to the deviation, work order, dispensing entries and batch evidence. Preserve the as-found configuration and examine whether other work orders used the same setup before narrowing scope.

Treat configuration failure as a hypothesis until controlled challenges support it. An operator-error explanation remains untested without evidence distinguishing user actions from system behaviour; retraining alone does not demonstrate resolution.

If controlled challenges confirm the configuration hypothesis, link the configuration change and supporting instructions through the site's applicable change-control process. Approval and execution records demonstrate implementation. Separately, test correct operation across the intended settings against predefined criteria and retain the observations as effectiveness evidence. Propose closure only when those results and the assessment of other work orders support it; otherwise revisit the cause, action or scope.

CAR Workflow and Decision Gates
  1. 1
    RegisterLink the originating observation and assign ownership.
  2. 2
    ContainAssess affected scope and immediate controls.
  3. 3
    InvestigateTest causes and select the investigation route.
  4. 4
    Approve planReview actions, responsibilities and effectiveness criteria.
  5. 5
    ImplementRetain evidence that approved actions occurred.
  6. 6
    Evaluate effectivenessCompare relevant observations with predefined criteria.
  7. 7
    DecideAuthorised reviewer closes, extends or returns the request.
Operational practice: each handoff connects an accountable owner with reviewable evidence.

06Route by product risk, recurrence and ownership

CAR triage commonly considers potential product impact, affected scope, detectability, recurrence and uncertainty. Assess which batches, products, sites or customers may be affected; whether existing controls would detect the problem before use; and what remains unknown. Severity labels are site-defined categories, not universal regulatory classifications. Record the reasoning, not just the label, in the CAR or linked quality risk register.

Separate immediate containment priority from the investigation and corrective-action schedule. An urgent need to isolate potentially affected material does not establish how long a defensible investigation will take. Set distinct milestones for containment confirmation, investigation findings, action delivery and effectiveness review through the site's procedure or supplier agreement.

Assign an accountable CAR owner and select reviewers for the issue: quality, manufacturing, engineering, laboratory, purchasing or supplier quality. Use supplier risk management to inform supplier-facing routing. Route cross-site or cross-product patterns to an owner with authority to evaluate the broader process, rather than letting local requests close independently.

For an extension, record the justification, current containment, residual risk, revised commitment and approving role. A changed due date alone does not explain whether continued operation remains acceptable.

Define reassessment triggers: expanding scope, ineffective containment, new complaints, contradictory evidence or repeated missed commitments. Reassessment commonly revisits priority, ownership, containment and escalation level; it is not merely another reminder to the same assignee.

07Supplier CARs: assess the response, not just its arrival

A supplier corrective action request (SCAR) commonly packages the affected material or service, purchase and delivery references, observed problem, supporting evidence and requested response milestones. Link the originating receiving discrepancy so the supplier can distinguish the documented observation from an initial suspicion about its cause.

Keep separate supplier and customer owners. The supplier provides its investigation and action evidence; the receiving organisation evaluates whether the response addresses its affected scope. Use supplier qualification history and the applicable quality agreement to interpret commitments, response expectations and escalation routes rather than assuming every supplier follows the same process.

Review the evidence behind the response

A practical acceptance review tests completeness, causal reasoning, action-to-cause linkage, implementation evidence and the proposed effectiveness method. Ask whether the finding also affects other supplied materials or production locations. A completed supplier template is an organised response, not sufficient evidence by itself: each conclusion needs support that the customer can evaluate.

Worked case: outdated allergen declaration

Assume a food manufacturer receives packaging carrying an outdated allergen declaration. Track the potentially affected scope by deliveries and material lots. Before selecting a cause, compare the customer's approved artwork, records of revision transmission and acknowledgement, and the supplier's production setup. These comparisons distinguish an incorrect instruction from a transfer failure or use of an obsolete production file.

Replacement packaging addresses the affected delivery. If the investigation confirms a revision-transfer failure, the corrective action instead targets the transfer and approval process. Evaluate the supplier's implementation evidence against the customer's approved artwork, then use subsequent relevant deliveries for an effectiveness check. Select deliveries that exercise the changed process; unchanged repeat orders may not test revision transfer.

If the response is rejected, record specific evidence gaps and the resubmission request, including what would resolve each gap. Preserve response versions, attachments and the customer's review decision so acceptance traces to the actual response reviewed—not merely the supplier's latest file or the date a form arrived.

08Effectiveness checks and metrics that distinguish completion from success

As industry practice, define the effectiveness question before reviewing results: which failure mechanism should change, which observations can test that expectation, and what constitutes failure or insufficient evidence? Choose exposure that exercises the mechanism—relevant production runs, supplier deliveries or challenged operating conditions. Elapsed time alone says little when the process has remained idle.

No detected recurrence is not proof that the changed control addresses the cause. Detection coverage, operating conditions and opportunities for failure affect that conclusion. Record these limits; do not attach unsupported statistical-confidence claims to a closure decision.

Worked case: device packaging seal width

Assume a medical-device packaging process has variable seal width, measured in millimetres, and investigation links the variation to an adjustable setup feature. The action adds a positive stop and locking adjustment. Installation records and setup instructions support implementation completion; they do not establish effectiveness.

Before testing, define seal-width acceptance criteria, the intended operating range, challenge conditions and relevant subsequent production exposure. Use the approved parameter tolerance band, rather than limits selected after seeing results. Challenge the changed setup across that range, then review measurements from relevant production runs. Passing results under the planned conditions support an effectiveness decision within that scope. A criterion breach triggers failure assessment; insufficient production exposure leaves the check pending, not passed. The reviewer records the evidence and reasoning supporting closure.

Metrics with explicit counting rules

Let P be the reporting period and T its closing date. Use these cohort rules consistently; report exclusions separately. Shares are fractions, not counts.

MetricDefinition and unitInterpretation limit
Response lead timeFor CARs receiving their first substantive response in P: response date − issue date, in calendar days; report the median.Exclude unanswered CARs from the median; show their count and age separately. Speed does not establish response quality.
Overdue shareAt T: overdue open CARs / all open CARs with due dates; fraction.Exclude undated CARs from the denominator and report them separately. Due-date changes can conceal delay.
Effectiveness pass shareChecks passed in P / all checks completed in P; fraction.Completed means passed or failed. Exclude pending checks and show them separately; never count insufficient evidence as a pass.
Reopened shareCARs closed in P and reopened by T / all CARs closed in P; fraction, counting each CAR once.Exclude earlier closure cohorts. Recent closures have less follow-up; compare cohorts at equivalent follow-up.
Recurrence per relevant exposureSame-mechanism recurrence events in P / relevant exposure units in P; events per run or delivery.Match numerator and denominator scope. Exclude unrelated events and exposures; report unclassified events separately. No exposure means not evaluable.

Stratify by supplier, product or severity where differences affect interpretation; do not pool unlike exposure units.

09Keep evidence connected when systems or supplier responses fail

Treat CAR integration controls as implementation practices, not additional regulatory requirements or V5 capability claims. In MES–QMS integration, map the CAR to authoritative deviation, complaint, audit, supplier, batch, laboratory and change-control records using stable identifiers rather than copied titles.

Maintain an ownership map naming the authoritative system for each status and evidence item. For example, the QMS may own CAR review status, the supplier portal the submitted response, MES the batch execution record, and LIMS the laboratory result. Record the source identifier, revision and transfer status at each handoff; distinguish successful receipt from evidence acceptance.

  • Duplicate imports or retries: retain the external identifier and check it before creating a request. Associate a retry with the existing CAR and preserve its original history rather than creating competing requests.
  • Failed transfers or missing attachments: expose the exception to a named owner, reconcile against the originating record and keep affected review decisions pending until the relevant evidence is available. A delivered message does not establish attachment completeness.
  • Revised supplier responses or investigation conclusions: retain the earlier version, identify dependent reviews and reassess them against the revision. Do not let stale approval evidence represent a materially changed response.

Keep evidence assessment and approval with authorised people. Use an audit trail review workflow to inspect revisions and recovery history before accepting the reconciled record.

Batch Context

V5 Ultimate’s batch record includes lab samples, QC check results, equipment used, checklists, electronic signatures and deviations. This provides batch context, not CAR workflow automation or compliance certification.

10CAR failure modes and a practical implementation checklist

Use these practice-based checks to test decision quality, not merely form completion. Apply the terminology from the earlier comparison section and the evidence structure from the field section.

Failure modeObservable symptomControl to test
Vague problem statementsReviewer cannot identify what failed.Observation identifies the affected process and expected condition.
Unsupported causesConclusion rests on assertion.Evidence supports the cause and addresses competing explanations.
Actions detached from causesTasks lack causal links.Each corrective action addresses an identified cause.
Missing scope expansionOnly the triggering lot is considered.Related products, lots and processes are assessed.
Unreviewed extensionsDates move without explanation.Approval records rationale, interim controls and revised commitments.
Closure driven only by overdue metricsRequests close before results mature.Closure follows the effectiveness criteria covered earlier.

Implementation checklist

  • Agree terminology and escalation criteria across participating teams.
  • Name owners and approvers, including delegated coverage.
  • Control evidence references so reviewers retrieve the intended version.
  • Define supplier-response acceptance rules and who applies them.
  • Establish extension and reopening routes with recorded decisions.
  • Define metric denominators and inclusion rules.
  • Test recoverable record handoffs, including failed transfers and reconciliation.

Review checklist

Select a completed request. Trace its originating observation through scope, investigation, action evidence, effectiveness result and approval. Examine an overdue or reopened request to test the exception path rather than assuming the normal workflow covers it.

Check whether management review identifies recurring causes, ineffective controls or resource constraints, rather than reporting only closed-request volume. Look for decisions and assigned follow-up where those patterns appear.

The practical usability test: an independent reviewer can understand the decision and locate its supporting evidence without reconstructing the history from email.

Frequently asked questions

Q.Can a CAR be closed without opening a separate CAPA record?+

Yes, where the organisation’s procedure allows the CAR itself to carry the investigation, actions, effectiveness evidence and closure approval. CAR is an industry-practice label, not a prescribed record format. A separate [CAPA record](/glossary/capa) is useful when broader systemic work needs its own ownership or governance. Record the rationale for that decision and retain links to the originating [deviation](/glossary/deviation). Closing the request should not leave unresolved actions hidden in correspondence or duplicate records with conflicting status.

Q.Who should accept a supplier response when purchasing and quality disagree?+

Use the decision authority defined in the supplier-quality procedure or agreement, rather than resolving the disagreement through commercial seniority. A practical division gives purchasing ownership of commercial commitments and quality ownership of technical adequacy. Document the disputed evidence, material risk and escalation decision. If acceptance could change [supplier qualification](/glossary/supplier-qualification), route that decision through its designated approver. Commercial urgency can inform [supplier risk management](/glossary/supplier-risk-management), but should not substitute for evidence that the proposed action addresses the failure.

Q.What should happen when the suspected root cause cannot be confirmed?+

Keep the suspected cause explicitly provisional. Record what supports it, what contradicts it and which tests or records could distinguish it from competing explanations. A practical [root cause analysis](/glossary/root-cause-analysis) also documents unavailable evidence and investigation limits. Risk-reducing actions may still be justified, but describe them as controls against plausible failure mechanisms rather than proof of a confirmed cause. Set follow-up monitoring and closure criteria that reflect the remaining uncertainty instead of forcing a definitive conclusion.

Q.How should an overdue CAR be handled when containment remains effective?+

Treat effective containment as a reason to reassess risk, not as evidence that permanent correction is complete. Document the delay, confirm that containment still covers current operations, and assess its dependence on extra inspection, staffing or supplier cooperation. Assign a revised milestone with an accountable owner and an approved extension rationale. Repeated extensions are useful inputs to [management review](/glossary/management-review); unresolved exposure can also be tracked in the [quality risk register](/glossary/quality-risk-register) while the CAR remains open.

Q.Can several affected lots, products or sites share the same CAR?+

Yes, as a practical record structure when a common failure mechanism and coordinated actions justify grouping. Preserve lot, product and site traceability, local responsibilities and separate effectiveness results where conditions differ. For US drug products under [21 CFR 211.192](https://www.ecfr.gov/current/title-21/section-211.192), the investigation must extend to other batches of the same drug product and other drug products potentially associated with the failure or discrepancy. A [backward genealogy trace](/glossary/backward-genealogy-trace) can help map that scope; a shared identifier alone does not demonstrate adequate coverage.

Q.What effectiveness evidence is useful when a defect is rare or seasonal?+

Use evidence tied to opportunities for failure, not simply elapsed time without a complaint. For a seasonal packaging defect, examine production under the relevant humidity, storage and transport conditions. For a rare setup error, assess representative changeovers and whether the revised control detects or prevents the mechanism. Define the effectiveness check before collecting results, including exposure, acceptance criteria and review ownership. Where representative exposure has not occurred, distinguish completed implementation from effectiveness that remains unproven.

Q.When is reopening a CAR better than raising a new request?+

Reopening is usually more informative when recurrence undermines the original cause conclusion, action implementation or effectiveness decision. A new request is generally clearer when the mechanism, responsible process or required response is materially different. Preserve the original closure decision and evidence rather than overwriting them, and cross-reference any new event. If a later process modification explains the recurrence, examine its [change control](/glossary/change-control) history before deciding. The record structure should make the failed assumption and subsequent accountability easy to follow.

Q.Does accepting a supplier's CAR response authorise use or release of the material?+

No. In a sound workflow, accepting the response records agreement with the supplier’s investigation or action plan; material disposition remains a separate decision by authorised personnel. A persuasive corrective action does not establish that previously delivered stock is acceptable. Link the CAR to the relevant [receiving discrepancy](/glossary/receiving-discrepancy), affected inventory and testing or assessment results. Record any use or release decision through the designated disposition process, such as an [electronic release record](/glossary/electronic-release-record), without treating supplier-response acceptance as its approval.

Primary sources

  • 21 CFR 211.192 — Production record review
  • 21 CFR Part 820 — Quality Management System Regulation
  • ICH Q10 Pharmaceutical Quality System
Software that covers CAR
V5 Ultimate Medical Device MES
Device history records built from signed steps at the workstation: component lots, configured step order, inspections, UDI and…
V5 Ultimate CAPA Software
Root cause, corrective and preventive actions and effectiveness checks sit with the source event, so owners can see what is open…
V5 Ultimate (QMSR)
The FDA Quality Management System Regulation (QMSR) — the harmonized replacement for 21 CFR 820 — became effective 2 February…
V5 Ultimate ISO 13485 QMS
Design controls with a live requirements-trace matrix, ISO 14971 risk file linked to software requirements per IEC 62304, CAPA /…
Talk to us about CAR

Want to see how CAR could fit into your own records and workflows? Explore the related V5 pages or talk to our team about what applies to your operation.

Start free
Back to glossary
Where this term comes up
PharmaceuticalMedical DevicesDietary SupplementsFood Processing
Inside V5
  • → Audits whose findings reach an owner.
  • → QMS — quality records next to the work they concern.
Example reports
V5Ultimate

Sample report

CAPA Record

Quality system

CAPA RecordView on screen or print
V5Ultimate

Sample report

Complaint File

Quality system

Complaint FileView on screen or print
→ All example reports
Regulatory anchors
  • ISO 13485:2016 cl. 8.5.2–8.5.3 via 21 CFR 820.10 (QMSR; replaced former 820.100)
  • ISO 13485 §8.5.2
  • ISO 9001 §10.2
  • ICH Q10 §3.2.2
Related terms
  • → CAPA
  • → NCR
  • → Deviation
  • → 5 Whys
  • → 8D

Next Step

Try V5 with your own records, or ask a question first. Ask V5 opens with an editable question; nothing is sent until you choose to.

Start your free trial Browse All Features

Showing the site for the United States. Local spelling, dates and prices are applied automatically; change the language at the top of the page.

V5 Ultimate
Ultimate

Warehouse, quality and manufacturing software for regulated operations.

ProductIndustriesPricingResourcesSecurity & TrustCompanyLegal Centre

© S.G. Systems, LLC